Figure 1: Heparin catalysis of thrombin inhibition by antithrombin. Knowledge of the determinants of antithrombin specificity and the size requirement for bridging thrombin has led to the development ...
The assay now can measure antithrombin (AT) activity levels for people treated with Qfitlia Qfitila will support people living with hemophilia A or B, with or without inhibitors, by helping to ...
A research group consisting of Professor Masahiro Nishibori (Specially Appointed Professor）, Department of Translational Research and Drug Development, Faculty of Medicine, Dentistry and ...
We identified a novel mechanism of hereditary thrombosis associated with antithrombin resistance, with a substitution of arginine for leucine at position 596 (p.Arg596Leu) in the gene encoding ...
Thrombate III is the only antithrombin concentrate approved in both adult and pediatric patients for hereditary antithrombin deficiency. The Food and Drug Administration (FDA) has expanded the ...
INNOVANCE Antithrombin assay is a cutting-edge, ready-to-use chromogenic reagent for the automated determination of antithrombin (AT) activity. It is highly accurate even at low activity levels and ...
The Case: A previously healthy 24-year-old man presented to the emergency department with sudden onset of severe periumbilical and right costovertebral pain accompanied by nausea and vomiting. His ...
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients over 12 years of age with hemophilia A or B. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback